<DOC>
	<DOC>NCT00180635</DOC>
	<brief_summary>The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in exhaled breath condensate, induced sputum, nasal lavage and mouth wash fluid in healthy non-smokers, current smokers and patients with COPD.</brief_summary>
	<brief_title>NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Pimagedine</mesh_term>
	<criteria>Healthy nonsmokers Normal spirometry (FEV1 &gt;90 % predicted; exhaled NO bigger than or equal to 10 ppb; flow 50 ml/s) At risk (current smokers) Normal spirometry, with or without chronic symptoms (cough, sputum production) FEV1 reversibility of &lt;15% after inhaled beta2agonists* Moderate COPD FEV1 greater than or equal to 30% and &lt; 80% FEV1/FVC &lt; 70% predicted FEV1 reversibility of &lt;15% after inhaled beta2agonists With or without chronic symptoms (cough, sputum production, dyspnea) Able to comprehend and grant a written informed consent Concomitant use or pretreatment within the last 4 weeks with oral steroids Respiratory infection within 4 weeks prior to entry into the trial Females who are pregnant or lactating History of current or past drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>